Cha Han Gyu, Kim Dong Gyu, Choi Joon Ho
Department of Plastic and Reconstructive Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon 14584, Korea.
Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon 14584, Korea.
Vaccines (Basel). 2022 Jun 16;10(6):964. doi: 10.3390/vaccines10060964.
Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseases, may be considered. Herein, we report the case of a 66-year-old woman who experienced prolonged ipsilateral supraclavicular lymph node enlargement after the second dose of the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccine, which was eventually diagnosed as extrapulmonary tuberculosis.
2019冠状病毒病（COVID-19）疫苗接种后出现淋巴结病是一种常见的副作用，通常在数天至数周内消退，仅建议进行观察。然而，对于持续性淋巴结病，可能需要考虑其他可能性，包括恶性肿瘤或其他淋巴增殖性疾病。在此，我们报告一例66岁女性病例，该患者在接种第二剂ChAdOx1（牛津-阿斯利康）COVID-19疫苗后出现同侧锁骨上淋巴结长期肿大，最终被诊断为肺外结核。
